BCHE and Alzheimer disease: It is worth noting that the AD drugs in clinical are broadly classified into two categories, including cholinesterase inhibitors and a NMDA receptor antagonist, each class of which has a different mechanism of action from that of MP, indicating that a combination therapy strategy involving MP holds enormous potential in significantly improving treatment outcomes for AD.